Edwards Lifesciences (EW) Rating Reiterated by Cowen

Cowen reaffirmed their buy rating on shares of Edwards Lifesciences (NYSE:EW) in a report published on Tuesday. Cowen currently has a $165.00 target price on the medical research company’s stock.

A number of other research analysts have also commented on EW. Canaccord Genuity restated a buy rating and issued a $137.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, November 29th. BMO Capital Markets restated a buy rating and issued a $137.00 price objective on shares of Edwards Lifesciences in a research note on Friday, December 8th. JPMorgan Chase & Co. lowered shares of Edwards Lifesciences from an overweight rating to a neutral rating in a research note on Tuesday, January 2nd. Evercore ISI started coverage on shares of Edwards Lifesciences in a research note on Wednesday, January 3rd. They issued an outperform rating and a $140.00 price objective on the stock. Finally, Barclays upgraded shares of Edwards Lifesciences from an equal weight rating to an overweight rating and lifted their price objective for the company from $125.00 to $135.00 in a research note on Thursday, January 4th. Three equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $144.16.

How to Become a New Pot Stock Millionaire

Shares of Edwards Lifesciences (EW) opened at $135.32 on Tuesday. Edwards Lifesciences has a one year low of $92.44 and a one year high of $143.22. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.41 and a current ratio of 1.80. The company has a market cap of $28,836.25, a price-to-earnings ratio of 36.13, a P/E/G ratio of 2.01 and a beta of 0.56.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, February 1st. The medical research company reported $0.94 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.91 by $0.03. The firm had revenue of $888.50 million for the quarter, compared to analyst estimates of $868.45 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.78%. Edwards Lifesciences’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same period last year, the business earned $0.75 EPS. analysts predict that Edwards Lifesciences will post 4.52 earnings per share for the current fiscal year.

Edwards Lifesciences declared that its Board of Directors has initiated a share repurchase program on Thursday, December 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

In other news, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction dated Thursday, December 28th. The shares were sold at an average price of $114.08, for a total transaction of $604,624.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director William J. Phd Link sold 12,000 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $122.24, for a total transaction of $1,466,880.00. Following the transaction, the director now owns 24,596 shares in the company, valued at $3,006,615.04. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 175,703 shares of company stock worth $22,433,887. Company insiders own 2.13% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in EW. Canada Pension Plan Investment Board boosted its holdings in Edwards Lifesciences by 756.6% during the third quarter. Canada Pension Plan Investment Board now owns 6,193 shares of the medical research company’s stock worth $677,000 after buying an additional 5,470 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in Edwards Lifesciences by 4.0% during the third quarter. New York State Common Retirement Fund now owns 529,800 shares of the medical research company’s stock worth $57,912,000 after buying an additional 20,600 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in Edwards Lifesciences by 14.7% during the third quarter. Teacher Retirement System of Texas now owns 6,116 shares of the medical research company’s stock worth $669,000 after buying an additional 784 shares in the last quarter. Commonwealth Equity Services Inc boosted its holdings in Edwards Lifesciences by 5.1% during the third quarter. Commonwealth Equity Services Inc now owns 22,872 shares of the medical research company’s stock worth $2,500,000 after buying an additional 1,117 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Edwards Lifesciences in the third quarter valued at about $1,081,000. 82.89% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Edwards Lifesciences (EW) Rating Reiterated by Cowen” was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/3295350/edwards-lifesciences-ew-rating-reiterated-by-cowen.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Uniti Group Inc.  Expected to Announce Earnings of $0.63 Per Share
Uniti Group Inc. Expected to Announce Earnings of $0.63 Per Share
WageWorks  Cut to “Hold” at Zacks Investment Research
WageWorks Cut to “Hold” at Zacks Investment Research
Onix  Price Hits $0.0115 on Exchanges
Onix Price Hits $0.0115 on Exchanges
SuperCoin Hits Market Cap of $383,530.00
SuperCoin Hits Market Cap of $383,530.00
Barings Global Short Duratin Hgh Yld Fnd  Receiving Somewhat Negative Media Coverage, Analysis Finds
Barings Global Short Duratin Hgh Yld Fnd Receiving Somewhat Negative Media Coverage, Analysis Finds
Alliance National Municipal Income Fund  Receives Daily News Sentiment Rating of 0.42
Alliance National Municipal Income Fund Receives Daily News Sentiment Rating of 0.42


© 2006-2018 Ticker Report. Google+.